Drug/Software Combos Likely Won't Require Pre-Market Review By US FDA
Executive Summary
The agency explains that most drug-use-related apps will be considered promotional labeling, but sponsors should sometimes seek advisory comment. US FDA is seeking feedback from a variety of stakeholders on its discussion proposal for regulating prescription-drug-focused software.